Review
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 14, 2022; 28(26): 3047-3062
Published online Jul 14, 2022. doi: 10.3748/wjg.v28.i26.3047
Role of baicalin as a potential therapeutic agent in hepatobiliary and gastrointestinal disorders: A review
Risha Ganguly, Ashutosh Gupta, Abhay K Pandey
Risha Ganguly, Ashutosh Gupta, Abhay K Pandey, Department of Biochemistry, University of Allahabad, Allahabad (Prayagraj) 211002, Uttar Pradesh, India
Author contributions: Ganguly R performed the literature review and wrote the manuscript; Ganguly R and Gupta A made the tables and figures; Pandey AK conceptualized the idea, critically reviewed and revised the manuscript; All authors have read and approved the final manuscript.
Supported by University Grants Commission, New Delhi, India in The Form of UGC-Junior and Senior Research Fellowships.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Abhay K Pandey, PhD, Full Professor, Department of Biochemistry, University of Allahabad, Faculty of Science, Katra, Allahabad (Prayagraj) 211002, Uttar Pradesh, India. akpandey23@rediffmail.com
Received: January 16, 2022
Peer-review started: January 16, 2022
First decision: March 8, 2022
Revised: March 21, 2022
Accepted: May 21, 2022
Article in press: May 21 2022
Published online: July 14, 2022
Processing time: 177 Days and 12.3 Hours
Core Tip

Core Tip: Baicalin possesses therapeutic efficacy against hepatic and gastrointestinal diseases including hepatic fibrosis, xenobiotic-induced liver injury, fatty liver disease, viral hepatitis, cholestasis, ulcerative colitis, hepatocellular and colorectal cancer. The drug action is mediated through its interaction with the gut microbiota, modulation of several signaling pathways, and inflammatory factors. The limitations of low solubility, permeability, and bioavailability pose challenges in the therapeutic applications. The different modes of drug delivery used in the transport of baicalin for ready absorption have paved the way for its use as a pharmacological agent against hepato-intestinal disorders.